



Axela and VWR International sign a North American Distribution Agreement

TORONTO, CANADA and WEST CHESTER, PA, January 15, 2008 – Axela Inc., a recognized innovator in protein interaction technology and VWR International, LLC, today announced that the two companies have entered into a distribution agreement for North America. VWR is a leader in the research laboratory supply industry, with a global pharmaceutical, biotechnology, government and academic customer-base.

Under the Agreement, VWR will distribute Axela's proprietary dotLab™ system and reagents across North America. This arrangement significantly expands VWR's instrumentation offerings in the protein research sector. Axela's experienced field scientists and territory managers will provide additional commercial and technical support for VWR's sales and marketing efforts.

"We are excited to work with VWR International to make our products broadly available to the \$20B protein research industry," commented Rocky Ganske, Axela CEO. "Initial applications are focused on accelerating the study of biomolecular interactions, optimizing protein expression and the rapid development of quantitative immunoassays. Axela is committed to providing cutting-edge products and integrated total solution platforms. The combination of these offerings with VWR International's leading position in the Life Science area will lead to rapid growth in dotLab system placements. It will also provide a solid foundation for future research and clinical offerings."

"Axela is a recognized developer of innovative life sciences and healthcare technologies, with a first-rate R&D capability," said Brian Kerslake, VWR Vice President of Life Science. "Initial acceptance has demonstrated there is a significant demand for Axela's products in the market today. We are very excited to enter into a distribution agreement and see a great future in this relationship."

"The strategic addition of Axela's innovative products and technologies to our life science portfolio significantly enhances VWR's network of suppliers," said Kerslake. "Our relationship will continue to strengthen VWR's ability to provide customers with superior solutions and leading-edge technology."

About VWR International, LLC

VWR International is a leader in the global research laboratory industry with worldwide sales of \$3.3 billion US dollars. VWR's business is highly diversified across products and services, geographic regions and customer segments. The company offers products from a wide range of manufacturers, to a large number of customers primarily in North America, Europe and other locations. VWR's principal customers are major pharmaceutical, biotechnology, chemical, technology, clinical, food processing and consumer product companies, universities and research institutes, governmental agencies, environmental testing organizations, and primary and secondary schools. VWR distributes a diversified product mix, including chemicals, glassware and plasticware, equipment and instruments, furniture, protective apparel, production and safety products, and other life science and laboratory products and supplies. VWR supports its customers by providing storeroom management, product procurement, supply chain systems integration, technical services and laboratory bench top delivery. VWR maintains operations in over 20 countries and employs over 6,000 people worldwide. VWR International is headquartered in West Chester, Pennsylvania. VWR-G

For more information on VWR International, phone 1-800-932-5000, visit www.vwr.com, or write, VWR International, 1310 Goshen Parkway, P.O. Box 2656, West Chester, PA 19380-0906.

VWR and design are registered trademarks of VWR International, LLC.

About Axela, Inc.

Axela has developed a proprietary technology for real time protein detection, characterization and monitoring directly in biological samples. The Company's products provide Life Science and Clinical Researchers simple tools and reagents to study interactions, expand the utility of traditional immunoassays and access novel categories of diagnostic markers. Participating in the research market provides unique access to novel discoveries that form the basis of a growing content pipeline for future multiplex diagnostic offerings. Axela is a privately-held company with operations in Toronto and California whose major investor is VenGrowth Private Equity Partners Inc., one of Canada's premier private equity managers. For more information, please visit www.axela.com or contact:

Owen Gordon, Director, Finance & Corporate Development
Axela Inc., Phone: (416) 260-9050 x2243
E-mail: o.gordon@axela.com

Brian J. Kerlake
Vice President - Life Science
VWR International
Office: 610-429-2828
Fax: 484-881-5895
Email: Brian_Kerlake@vwr.com